Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting
Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting
复制标题
DOI：
10.1200/jco.2016.72.0177
复制
发表时间：
2017-08-01
影响因子：
45.3
通讯作者：
Valteau-Couanet, Dominique
中科院分区：
文献类型：
--
作者：
Park, Julie R.;Bagatell, Rochelle;Valteau-Couanet, Dominique
二十多年前，一个国际工作组建立了国际神经母细胞瘤反应标准（INRC），以评估儿童神经母细胞瘤的治疗反应。然而，这个系统需要修改，以纳入现代成像技术和新的方法来量化骨髓疾病，以前没有广泛使用。美国国家癌症研究所主办的临床试验规划会议在2012年更新和完善响应标准为患者neuroblastoma.MethodsMultidisciplinary调查13个国家的审查数据，通过合作组，财团，和单一机构进行的已发表的试验。来自前瞻性和回顾性试验的数据被用来完善INRC。2011年至2015年每月召开一次国际电话会议，通过工作组领导和国家癌症研究所临床试验计划会议领导理事会的审查达成共识。ResultsOverall response in the revised INRC将整合原发肿瘤、软组织和骨转移以及骨髓中的肿瘤反应。如果肿瘤为MIBG非亲嗜性，将使用实体瘤疗效评价标准（RECIST）和碘-123（I-123）-间碘苄胍（MIBG）扫描或[F-18]氟脱氧葡萄糖-正电子发射断层扫描评估原发性和转移性软组织部位。I-123-MIBG扫描或[F-18]氟脱氧葡萄糖-正电子发射断层扫描用于MIBG-非恶性疾病，取代锝-99m二磷酸盐骨显像用于骨髓转移评估。将通过组织学或免疫组织化学和细胞学或免疫细胞学评估骨髓。骨髓与
PurposeMore than two decades ago, an international working group established the International Neuroblastoma Response Criteria (INRC) to assess treatment response in children with neuroblastoma. However, this system requires modification to incorporate modern imaging techniques and new methods for quantifying bone marrow disease that were not previously widely available. The National Cancer Institute sponsored a clinical trials planning meeting in 2012 to update and refine response criteria for patients with neuroblastoma.MethodsMultidisciplinary investigators from 13 countries reviewed data from published trials performed through cooperative groups, consortia, and single institutions. Data from both prospective and retrospective trials were used to refine the INRC. Monthly international conference calls were held from 2011 to 2015, and consensus was reached through review by working group leadership and the National Cancer Institute Clinical Trials Planning Meeting leadership council.ResultsOverall response in the revised INRC will integrate tumor response in the primary tumor, soft tissue and bone metastases, and bone marrow. Primary and metastatic soft tissue sites will be assessed using Response Evaluation Criteria in Solid Tumors (RECIST) and iodine-123 (I-123)-metaiodobenzylguanidine (MIBG) scans or [F-18] fluorodeoxyglucose-positron emission tomography scans if the tumor is MIBG nonavid. I-123-MIBG scans, or [F-18] fluorodeoxyglucose-positron emission tomography scans for MIBG-nonavid disease, replace technetium-99m diphosphonate bone scintigraphy for osteomedullary metastasis assessment. Bone marrow will be assessed by histology or immunohistochemistry and cytology or immunocytology. Bone marrow with